Reported Earnings • 22h
Third quarter 2026 earnings released: EPS: US$0.18 (vs US$3.35 loss in 3Q 2025) Third quarter 2026 results: EPS: US$0.18 (up from US$3.35 loss in 3Q 2025). Revenue: US$21.9m (up 7.5% from 3Q 2025). Net income: US$3.58m (up US$70.9m from 3Q 2025). Profit margin: 16% (up from net loss in 3Q 2025). The move to profitability was primarily driven by lower expenses. Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in Europe. 공시 • Jun 18
Altaris, LLC entered into a definitive agreement to acquire Simulations Plus, Inc. (NasdaqGS:SLP) from Walter Woltosz and others for approximately $370 million. Altaris, LLC entered into a definitive agreement to acquire Simulations Plus, Inc. (NasdaqGS:SLP) from Walter Woltosz and others for approximately $370 million on June 16, 2026. Under the terms of the agreement, Simulations Plus common stockholders will receive $18.5 per share, representing a premium of 26% to Simulations Plus’ 60-day volume-weighted average price as of June 15, 2026. The transaction will be financed through a combination of committed equity and debt financing through funds affiliated with Altaris. Upon completion of the transaction, Simulations Plus’ headquarters is expected to remain in Research Triangle Park, North Carolina. Upon closing, Simulations Plus will become a privately held subsidiary of Altaris and its common stock will no longer be traded on the Nasdaq Stock Exchange. Additionally, Altaris anticipates Simulations Plus, Inc. will be combined with Chemical Computing Group.
The transaction, which was unanimously approved by the Simulations Plus Board of Directors, is subject to customary closing conditions including the receipt of approval of the Simulations Plus stockholders, required regulatory, and other similar approvals and closing conditions. The transaction is currently expected to close in the calendar fourth quarter of 2026. In connection with the execution of the merger agreement, Simulations Plus cofounder and director Dr. Walter Woltosz has entered into a voting and support agreement with Altaris pursuant to which he has agreed to vote all of the shares beneficially owned by him in favor of the transaction.
Truist Securities, Inc. acted as financial advisor for Altaris, LLC. J.P. Morgan Securities LLC acted as financial advisor for Altaris, LLC. Morgan Stanley & Co. LLC acted as financial advisor for Simulations Plus, Inc. Procopio Cory Hargreaves & Savitch LLP acted as legal advisor for Simulations Plus, Inc. Kirkland & Ellis LLP acted as legal advisor for Altaris, LLC. Bass, Berry & Sims PLC acted as legal advisor for Altaris. 공시 • Jun 16
Simulations Plus, Inc. to Report Q3, 2026 Results on Jul 09, 2026 Simulations Plus, Inc. announced that they will report Q3, 2026 results on Jul 09, 2026 Board Change • May 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. Independent Director Sharlene Evans was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. 공시 • Apr 24
Simulations Plus, Inc. Announces Collaboration with Lonza Group Ag and U.S. Food and Drug Administration to Advance Predictive Frameworks for Complex Oral Drug Products Simulations Plus, Inc. had announced a funded research collaboration with Lonza Group AG and the U.S. Food and Drug Administration to develop and validate a mechanistic, predictive framework for assessing the in vivo performance of amorphous solid dispersion drug products. Mechanistic modeling approach and experimental integration designed to improve early risk identification, strengthen regulatory confidence, and expand AI-enabled workflows connecting data to decision-making. The collaboration evaluates whether advanced in vitro dissolution systems—particularly those incorporating dynamic gastrointestinal physiology—combined with mechanistic physiologically based biopharmaceutics modeling, can reliably predict key in vivo outcomes, including food effects and the impact of elevated gastric pH conditions. By establishing and validating these predictive capabilities, the collaboration aims to provide a scientific foundation for reducing reliance on certain clinical bioequivalence studies while maintaining the rigor and transparency required by regulators. Lonza will lead experimental work, including in vitro dissolution testing under fasted, fed, and elevated gastric pH conditions using advanced systems such as Controlled Transfer Dissolution, as well as the characterization and, where needed, manufacturing of amorphous solid dispersion formulation variants. Simulations Plus will lead the development and validation of in vitro–in vivo extrapolation frameworks using its DDDPlus® and GastroPlus® platforms, translating experimental data into predictions of in vivo pharmacokinetics and supporting virtual bioequivalence assessments. At the same time, it creates new opportunities to extend these capabilities into grounded AI-enabled workflow environments, where data, mechanistic models, and simulation outputs will be more directly connected. The Company will also contribute to interpretation within a regulatory context, ensuring alignment with evolving expectations for model-informed drug development. This work is supported in part through FDA funding and includes ongoing engagement with FDA scientists to directly align with regulatory priorities to advance model-informed drug development, modernize bioequivalence assessment for complex products, and reduce unnecessary reliance on human studies. By combining regulatory collaboration with open, non-proprietary data and validated methods based on real-world, FDA-approved amorphous solid dispersion products, the initiative is intended to inform future regulatory approaches and support broader adoption of science-based alternatives. 
